Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.

Singh D, D'Urzo AD, Donohue JF, Kerwin EM, Molins E, Chuecos F, Ribera A, Jarreta D.

Int J Chron Obstruct Pulmon Dis. 2019 Dec 6;14:2835-2848. doi: 10.2147/COPD.S217710. eCollection 2019. Review.

2.

Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective.

Singh D, D'Urzo AD, Donohue JF, Kerwin EM.

Respir Res. 2019 Jul 8;20(1):141. doi: 10.1186/s12931-019-1108-9. Review.

3.

Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices.

Krishnan JA, Nibber A, Chisholm A, Price D, Bateman ED, Bjermer L, van Boven JFM, Brusselle G, Costello RW, Dandurand RJ, Diamant Z, Van Ganse E, Gouder C, van Kampen SC, Kaplan A, Kocks J, Miravitlles M, Niimi A, Pizzichini E, Rhee CK, Soriano JB, Vogelmeier C, Román-Rodriguez M, Carter V, D'Urzo AD, Roche N.

Ann Am Thorac Soc. 2019 Sep;16(9):1143-1150. doi: 10.1513/AnnalsATS.201809-607OC.

PMID:
31162945
4.

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base.

D'Urzo AD, Singh D, Donohue JF, Chapman KR.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619850725. doi: 10.1177/1753466619850725. Review.

5.

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT.

D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Gil EG.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 26;14:479-491. doi: 10.2147/COPD.S185502. eCollection 2019.

6.

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.

D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 7;13:2805-2819. doi: 10.2147/COPD.S113306. eCollection 2018. Review.

7.

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.

D'Urzo AD, Kardos P, Wiseman R.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 4;13:1089-1104. doi: 10.2147/COPD.S160577. eCollection 2018. Review.

8.

Difficultés liées au diagnostic de déficit en α1-antitrypsine en soins de première ligne.

Ye Q, D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):e655-e658. French. No abstract available.

PMID:
28661883
Free Article
9.

Challenge of α1-antitrypsin deficiency diagnosis in primary care.

Ye Q, D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):899-901. No abstract available.

10.

Response.

D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):875-877. No abstract available.

11.

Why primary care guidelines are not prepared by family physicians.

D'Urzo AD.

Can Fam Physician. 2016 Nov;62(11):874. No abstract available.

12.

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.

Singh D, D'Urzo AD, Chuecos F, Muñoz A, Garcia Gil E.

Respir Res. 2017 May 30;18(1):106. doi: 10.1186/s12931-017-0583-0.

13.

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.

D'Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D'Andrea P, Hu H, Goyal P, Altman P.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 11;10:1599-612. doi: 10.2147/COPD.S81266. eCollection 2015.

14.
15.

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

D'Urzo AD, Rennard SI, Kerwin EM, Mergel V, Leselbaum AR, Caracta CF; AUGMENT COPD study investigators.

Respir Res. 2014 Oct 14;15:123. doi: 10.1186/s12931-014-0123-0.

16.

Response.

D'Urzo AD, Abitbol L.

Can Fam Physician. 2015 Feb;61(2):127. No abstract available.

17.

Effectiveness of omalizumab in severe persistent asthma under real-life conditions.

D'Urzo AD, Wong J.

Can Fam Physician. 2014 Jul;60(7):643-5. No abstract available.

18.

New therapy for managing moderate to severe chronic obstructive pulmonary disease.

Chou A, D'Urzo AD.

Can Fam Physician. 2014 Apr;60(4):352-4. No abstract available.

19.

Four-year trial of tiotropium in chronic obstructive pulmonary disease.

D'Urzo AD, Jugovic P, Jhirad R, Bouchard J.

Can Fam Physician. 2012 Aug;58(8):848-9. No abstract available.

20.

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators.

COPD. 2012 Apr;9(2):90-101. doi: 10.3109/15412555.2012.661492. Epub 2012 Feb 9.

PMID:
22320148
21.

Limitations of a spirometry interpretation algorithm.

D'Urzo AD, Tamari I, Bouchard J, Jhirad R, Jugovic P.

Can Fam Physician. 2011 Oct;57(10):1153-6. No abstract available.

22.

New spirometry interpretation algorithm: Primary Care Respiratory Alliance of Canada approach.

D'Urzo AD, Tamari I, Bouchard J, Jhirad R, Jugovic P.

Can Fam Physician. 2011 Oct;57(10):1148-52. No abstract available.

23.

Spirometry interpretation in primary care.

D'Urzo AD.

Can Fam Physician. 2011 Oct;57(10):1122. No abstract available.

24.

Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: yes.

D'Urzo AD.

Can Fam Physician. 2011 Aug;57(8):870, 872, 874, 876; discussion e277, e279. English, French. No abstract available.

25.

Asthma management made too SIMPLE.

D'Urzo AD, Jugovic P.

Can Fam Physician. 2010 Oct;56(10):1019-21. No abstract available.

26.

Asthma management in the real world: The perils of simplicity.

D'Urzo AD.

Can Fam Physician. 2010 Oct;56(10):976-7, e355-6. English, French. No abstract available.

27.

The SIMPLE trial.

D'Urzo AD.

Can Respir J. 2010 Mar-Apr;17(2):56. No abstract available.

28.

Must family physicians use spirometry in managing asthma patients?: NO.

D'Urzo AD.

Can Fam Physician. 2010 Feb;56(2):127, 129, 131, 133; discussion e50, e52. English, French. No abstract available.

29.

Safety of long-acting beta2-agonists in the management of asthma: a Primary Care Respiratory Alliance of Canada perspective.

D'Urzo AD, Jugovic P, Bouchard J, Jhirad R, Tamari I.

Can Fam Physician. 2010 Feb;56(2):119-20, 123-4. English, French. No abstract available.

30.

Diagnosis of asthma.

D'Urzo AD.

CMAJ. 2010 Jan 12;182(1):64. doi: 10.1503/cmaj.110-2010. No abstract available.

31.

The "Towards a Revolution in COPD Health" study: Comparing treatment strategies.

D'Urzo AD.

Can Fam Physician. 2008 May;54(5):740-1. No abstract available.

32.

Beta-agonists: all the facts please.

D'Urzo AD.

Can Fam Physician. 2007 Nov;53(11):1884-6; author reply 1886. No abstract available.

34.

Is it time for single-inhaler asthma therapy?

D'Urzo AD, Solanki V.

Can Fam Physician. 2006 Jul;52:859-60. No abstract available.

35.

Flexible asthma therapy.

D'Urzo AD, Solanki V.

Can Fam Physician. 2005 Dec;51:1633-4, 1636. No abstract available.

36.

CONtrol Centered Patient Treatment (CONCEPT).

D'Urzo AD.

Clin Ther. 2005 Aug;27(8):1312; author reply 1312-5. No abstract available.

PMID:
16199255
37.

Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma.

Chapman KR, Patel P, D'Urzo AD, Alexander M, Mehra S, Oedekoven C, Engelstätter R, Boulet LP.

Allergy. 2005 Mar;60(3):330-7.

PMID:
15679718
38.

Withdrawal of treatment in the ISOLDE study.

D'Urzo AD.

Chest. 2004 Jun;125(6):2368; author reply 2368. No abstract available.

PMID:
15189970
39.

Evaluation of a questionnaire to assess compliance with anti-asthma medications.

Walewski KM, Cicutto L, D'Urzo AD, Heslegrave RJ, Chapman KR.

J Asthma. 2004 Feb;41(1):77-83.

PMID:
15046381
40.

The role of spirometry in clinical practice.

D'Urzo AD.

Can Respir J. 2001 Sep-Oct;8(5):381-2. No abstract available.

PMID:
11694918
41.

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.

D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J; FOR-INT-03 Study Group.

Chest. 2001 May;119(5):1347-56.

PMID:
11348938
42.

Effectiveness and safety of salmeterol in nonspecialist practice settings.

D'Urzo AD, Chapman KR, Cartier A, Hargreave FE, Fitzgerald M, Tesarowski D.

Chest. 2001 Mar;119(3):714-9.

PMID:
11243947
43.

Conflicting message in the title.

D'Urzo AD.

Can Fam Physician. 2000 Jun;46:1263-4. No abstract available.

44.

Controlling asthma. Highlights of the 1999 Canadian Asthma Consensus Report.

D'Urzo AD.

Can Fam Physician. 2000 Apr;46:895-8, 902-4. English, French. No abstract available.

45.

Case report: allergic bronchopulmonary aspergillosis in asthma.

D'Urzo AD, McIvor AR.

Can Fam Physician. 2000 Apr;46:882-4. No abstract available.

46.

Leukotriene-receptor antagonists. Role in asthma management.

D'Urzo AD, Chapman KR.

Can Fam Physician. 2000 Apr;46:872-9. Review.

47.

Exercise limitation in chronic obstructive pulmonary disease (COPD)

D'Urzo AD.

Am J Respir Crit Care Med. 1999 Aug;160(2):756. No abstract available.

PMID:
10475696
48.

Phaseout of chlorofluorocarbons (CFCs) in metered-dose inhalers. Highlights of the Canadian initial transition strategy.

D'Urzo AD, D'Urzo DK.

Can Fam Physician. 1999 Jun;45:1544-6, 1556-7. English, French. No abstract available.

49.

Case report: pneumothorax and asthma.

D'Urzo AD, D'Urzo DK, Chapman KR.

Can Fam Physician. 1999 Jun;45:1524-5. No abstract available. Erratum in: Can Fam Physician 1999 Jul;45:1655.

50.

Change needed in asthma management guidelines.

D'Urzo AD.

Can Fam Physician. 1998 Jan;44:31, 33. No abstract available.

Supplemental Content

Loading ...
Support Center